Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia

Ali et al. (2021) studied Renal ischemia. Angiotensin II type 2 receptor agonist C21 was evaluated on Postischemic kidney injury, kidney dysfunction, and immune cell infiltration. C21 treatment before renal ischemia attenuated postischemic kidney injury and dysfunction, and enhanced IL-10-secreting CD4 T cells and FoxP3-secreting regulatory T cells during the repair phase.